- High soluble CD30, CD25, and IL-6 may identify patients with worse survival in CD30+ cutaneous lymphomas and early mycosis fungoidesMarshall E Kadin
Department of Dermatology, Boston University, Roger Williams Medical Center, Providence, Rhode Island 02908, USA
J Invest Dermatol 132:703-10. 2012..We conclude that (1) neoplastic cells of some CD30CLPD patients do not resemble Th2 cells, and that (2) high serum sCD30, sCD25, IL-6, and perhaps IL-8 levels may provide prognostic information useful for patient management...
- Current management of primary cutaneous CD30+ T-cell lymphoproliferative disordersMarshall E Kadin
Department of Dermatology and Skin Surgery, Boston University School of Medicine and Roger Williams Medical Center, Providence, Rhode Island 02908, USA
Oncology (Williston Park) 23:1158-64. 2009..Patients with localized cutaneous ALCL can be treated with irradiation. Extracutaneous spread of disease is an indication for multiagent chemotherapy. Other treatment alternatives are discussed...